FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Zacks Research increased their FY2025 earnings per share estimates for Bruker in a research report issued to clients and investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.68 for the year, up from their prior forecast of $2.67. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Several other research firms have also recently weighed in on BRKR. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Stifel Nicolaus cut their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. UBS Group assumed coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Finally, Barclays lowered their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Trading Up 2.2 %

NASDAQ BRKR opened at $45.97 on Friday. Bruker has a 12 month low of $44.11 and a 12 month high of $94.86. The stock has a 50 day moving average of $53.93 and a 200-day moving average of $58.57. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The company has a market cap of $6.97 billion, a PE ratio of 60.49, a PEG ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a dividend of $0.05 per share. The ex-dividend date is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.44%. Bruker’s payout ratio is 26.32%.

Hedge Funds Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in BRKR. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares during the period. Eagle Bay Advisors LLC increased its position in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. boosted its stake in Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares during the last quarter. Quadrant Capital Group LLC lifted its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 412 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.